Enhancing proteotoxic stress as an anticancer strategy - PubMed (original) (raw)

Comment

Enhancing proteotoxic stress as an anticancer strategy

Steven Grant. Oncotarget. 2011 Apr.

No abstract available

PubMed Disclaimer

Comment on

• Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
  Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Neznanov N, et al. Oncotarget. 2011 Mar;2(3):209-21. doi: 10.18632/oncotarget.246. Oncotarget. 2011. PMID: 21444945 Free PMC article.

Similar articles

• A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability.
  Workman P, Davies FE. Workman P, et al. Oncotarget. 2011 Apr;2(4):277-80. doi: 10.18632/oncotarget.266. Oncotarget. 2011. PMID: 21515932 Free PMC article. No abstract available.
• Heat shock proteins in cancer: targeting the 'chaperones'.
  Nahleh Z, Tfayli A, Najm A, El Sayed A, Nahle Z. Nahleh Z, et al. Future Med Chem. 2012 May;4(7):927-35. doi: 10.4155/fmc.12.50. Future Med Chem. 2012. PMID: 22571616 Review.
• Unfolded protein response to autophagy as a promising druggable target for anticancer therapy.
  Suh DH, Kim MK, Kim HS, Chung HH, Song YS. Suh DH, et al. Ann N Y Acad Sci. 2012 Oct;1271(1):20-32. doi: 10.1111/j.1749-6632.2012.06739.x. Ann N Y Acad Sci. 2012. PMID: 23050960 Free PMC article. Review.
• Emerging Cancer Therapeutic Targets in Protein Homeostasis.
  Bastola P, Oien DB, Cooley M, Chien J. Bastola P, et al. AAPS J. 2018 Aug 27;20(6):94. doi: 10.1208/s12248-018-0254-1. AAPS J. 2018. PMID: 30151644
• Molecular-targeted agents combination therapy for cancer: developments and potentials.
  Li F, Zhao C, Wang L. Li F, et al. Int J Cancer. 2014 Mar 15;134(6):1257-69. doi: 10.1002/ijc.28261. Epub 2013 Jun 12. Int J Cancer. 2014. PMID: 23649791 Review.

Cited by

• Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
  Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC, Dennis PA. Kawabata S, et al. Cell Death Dis. 2012 Jul 19;3(7):e353. doi: 10.1038/cddis.2012.87. Cell Death Dis. 2012. PMID: 22825471 Free PMC article.
• Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.
  Blagosklonny MV. Blagosklonny MV. Oncotarget. 2012 Dec;3(12):1711-24. doi: 10.18632/oncotarget.890. Oncotarget. 2012. PMID: 23565531 Free PMC article.
• Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
  Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon LI, Rosen ST, Budunova I. Lesovaya E, et al. Cell Cycle. 2013 Jan 1;12(1):133-44. doi: 10.4161/cc.23048. Epub 2012 Dec 19. Cell Cycle. 2013. PMID: 23255118 Free PMC article.
• Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
  Martinez-Useros J, Garcia-Foncillas J. Martinez-Useros J, et al. Biomed Res Int. 2016;2016:4873089. doi: 10.1155/2016/4873089. Epub 2016 Sep 1. Biomed Res Int. 2016. PMID: 27689078 Free PMC article. Review.
• The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
  Besse L, Kraus M, Besse A, Driessen C, Tarantino I. Besse L, et al. Sci Rep. 2023 Mar 17;13(1):4411. doi: 10.1038/s41598-023-31400-6. Sci Rep. 2023. PMID: 36932175 Free PMC article.

References

1. 1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. - PubMed
2. 1. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823–837. - PMC - PubMed
3. 1. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature. 1992;359(6395):554–556. - PubMed
4. 1. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007 - PubMed
5. 1. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519–529. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• P50 CA142509/CA/NCI NIH HHS/United States
• CA130805/CA/NCI NIH HHS/United States
• R01 CA100866/CA/NCI NIH HHS/United States
• R01 CA093738/CA/NCI NIH HHS/United States
• CA 100866/CA/NCI NIH HHS/United States
• RC2 CA148431/CA/NCI NIH HHS/United States
• CA142509/CA/NCI NIH HHS/United States
• CA93738/CA/NCI NIH HHS/United States
• CA148431/CA/NCI NIH HHS/United States
• P50 CA130805/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Impact Journals, LLC
  • PubMed Central